Direct oral anticoagulants: what can we learn?
- 277 Downloads
Direct oral anticoagulants (DOACs) represent an innovation because they avoid periodic laboratory monitoring, and also reduce cerebral bleeding. An examination of the performance of DOACs versus warfarin in randomized clinical trials dedicated to atrial fibrillation would reveal the poor performance of warfarin because the percentage of major bleeding is always above 3%; however, the percentage of major bleeding is less than half of that when the management is done in anticoagulation clinics (ACs). Several years ago, a common opinion was that ACs would disappear as soon as DOACs enter the market. We proposed then that ACs could be transformed into thrombosis centres (TCs) because we envisaged many new activities in terms of diagnostic tools and therapeutic choices. After the introduction of DOACs, the role of the ACs has been re-evaluated because their role may be crucial in selecting both the most appropriate diagnostic approach and the best therapeutic option (including anti-vitamin K drugs) for the single patient. TCs can organize a regular follow-up to improve patient adherence to DOACs. Marketing might have a role in the decision making of the single doctor. Efforts should be made for limiting the relationships between doctors and pharmaceutical companies. It seems reasonable to better prepare doctors, during their university courses, for them to develop a greater scientific culture that would enable them to critically read clinical studies and acquire an independent opinion. Ideally, an expert in haemostasis and thrombosis should handle new and old anticoagulants.
KeywordsDirect oral anticoagulants Anticoagulation clinics Warfarin Atrial fibrillation Thrombosis centers
Compliance with ethical standards
Conflict of interest
The authors declare that they have no competing interests.
Statement of human and animal rights
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was not required for this type of study.
- 1.Prisco D, Ageno W, Becattini C, D’Angelo A, Davì G, De Cristofaro R et al; SIMI (Italian Society of Internal Medicine); FADOI (Federation of Associations of Hospital Doctors on Internal Medicine); SISET (Italian Society for the Study of Haemostasis and Thrombosis) (2017) Italian intersociety consensus on DOAC use in internal medicine. Intern Emerg Med 12(3):387–406CrossRefGoogle Scholar
- 3.Palareti G, Antonucci E, Migliaccio L, Erba N, Marongiu F, Pengo V et al; Centers participating in the FCSA-START-Register (The ISCOAT 2016 study: Italian Study on Complications of Oral Anticoagulant Therapy-2016) (2017) Vitamin K antagonist therapy: changes in the treated populations and in management results in Italian anticoagulation clinics compared with those recorded 20 years ago. Intern Emerg Med 12(8):1109–1119Google Scholar
- 11.European Commission (2009) Enterprise and industry directorate-general. In: Notice to applicants. A guideline on summary of product characteristics (SmPC), revison 2, pp 1–29Google Scholar
- 13.Pengo V, Crippa L, Falanga A, Finazzi G, Marongiu F, Palareti G et al (2011) Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA). Thromb Haemost 106(5):868–876PubMedGoogle Scholar